Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00551070 · OUTCOME

Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ng/mL
Interval / dispersion
Inter-Quartile Range
Time frame
Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment

Analysis population: Eligible and Treated Patients with at least one post-dose pharmacokinetic time point available

Groups in this outcome

AZD6244

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD624442

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
AZD6244585Not reported3711100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        371
        upper Limit
        1100
        value
        585
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    units
    Participants
dispersion Type
Inter-Quartile Range
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    OG000
    title
    AZD6244
param Type
MEDIAN
population Description
Eligible and Treated Patients with at least one post-dose pharmacokinetic time point available
reporting Status
POSTED
time Frame
Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment
title
Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.
type
PRIMARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice